Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,063.56 -21.63 (-1.99%)

Official Closing Price Updated: 7:00 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

99 100 Next >

2 Magnificent S&P 500 Dividend Stocks Down 7% and 19% to Buy and Hold Forever ↗

September 20, 2025

These two underperforming stocks remain attractive for long-term dividend-seeking investors.

Via The Motley Fool

Topics Economy Stocks

Is Novo Nordisk Stock a Buy Now? ↗

September 20, 2025

A lot has gone wrong for the drugmaker recently.

Via The Motley Fool

Topics Economy

The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market

September 19, 2025

The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Peering Into Eli Lilly's Recent Short Interest ↗

September 18, 2025

Via Benzinga

Johnson & Johnson Unleashes Triple Threat: Bladder Cancer Breakthrough, Psoriasis Game-Changer, and Myasthenia Gravis Milestone Signal New Pharma Era

September 19, 2025

Johnson & Johnson (NYSE: JNJ) is making significant waves in the pharmaceutical landscape, announcing a trio of pivotal developments that underscore its robust pipeline and strategic focus on unmet...

Via MarketMinute

Could This New Drug Be The Safer Way To Fight Obesity? ↗

September 19, 2025

Skye Bioscience reported favorable Phase 1b nimacimab results, with analysts citing strong potential in obesity alongside GLP-1 therapies.

Via Benzinga

Eli Lilly's Dual Triumph: Mounjaro Expands Reach, Orforglipron Set to Revolutionize Oral Diabetes and Weight Loss Market

September 19, 2025

Eli Lilly (NYSE: LLY) is poised to further solidify its dominance in the burgeoning diabetes and weight loss markets following a cascade of overwhelmingly positive clinical trial results for its...

Via MarketMinute

Lilly's $5 Billion Virginia Investment: A Game Changer for GLP-1 and Oncology Drug Production

September 19, 2025

Eli Lilly and Company (NYSE: LLY) has announced a colossal $5 billion investment to establish a new, state-of-the-art manufacturing facility in Goochland County, Virginia. This significant expansion, a...

Via MarketMinute

Topics Artificial Intelligence Economy Government

Eli Lilly Poised for Blockbuster Q3 2025 with Skyrocketing EPS and Revenue Projections

September 19, 2025

Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is gearing up for a stellar third quarter of 2025, with analysts projecting massive earnings per share (EPS) and revenue growth. The optimistic...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

GLP-1 Titans Clash: Eli Lilly Challenges Novo Nordisk's Dominance in a Spiraling Market Battle

September 19, 2025

The pharmaceutical industry is witnessing an unprecedented showdown as Eli Lilly (NYSE: LLY) rapidly encroaches upon Novo Nordisk's (NYSE: NVO) long-held lead in the burgeoning GLP-1 (glucagon-like...

Via MarketMinute

Lilly's AI Gambit: TuneLab Poised to Reshape Biotech Drug Discovery Landscape

September 19, 2025

Eli Lilly and Company (NYSE: LLY) has unveiled its groundbreaking TuneLab Platform, an artificial intelligence (AI) and machine learning (ML) initiative designed to democratize advanced drug discovery...

Via MarketMinute

Topics Animal Testing Artificial Intelligence Intellectual Property

Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes

September 19, 2025

Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca...

Via MarketMinute

This Unstoppable Healthcare Stock Just Made a Move in AI: Time to Buy? ↗

September 19, 2025

Eli Lilly's initiative could make the company even more successful than it already is.

Via The Motley Fool

Topics Artificial Intelligence

Where Will Eli Lilly Be in 3 Years? ↗

September 19, 2025

With a market cap of $708 billion, Eli Lilly isn't far from becoming the first trillion-dollar healthcare company.

Via The Motley Fool

Why Shares in Novo Nordisk Soared This Week ↗

September 19, 2025

Positive results from the trial further indicate that the company is poised to win the next battle in the weight loss drug market.

Via The Motley Fool

Prediction: Viking Therapeutics Stock Will Double in Value Within the Next 12 Months ↗

September 19, 2025

Viking's stock took a beating last month, and it has opened up a glorious buying opportunity for investors.

Via The Motley Fool

Topics Bankruptcy

Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything ↗

September 18, 2025

Eli Lilly stock rises on FDA fast-track hopes for its oral GLP-1 obesity drug and $27B U.S. manufacturing expansion; it's a tough trade but solid long-term hold

Via MarketBeat

My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years ↗

September 18, 2025

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue.

Via Benzinga

Here's Why Novo Nordisk and Eli Lilly Could Still Be Absurdly Underrated Stocks to Buy Today ↗

September 18, 2025

Medicare and Medicaid coverage of GLP-1 weight loss drugs could be just what the doctor ordered for these two struggling stocks.

Via The Motley Fool

Topics Government

Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs ↗

September 18, 2025

The FDA's warnings to Eli Lilly, Novo Nordisk and Hims & Hers spotlight risks for ETFs tied to the weight-loss drug boom.

Via Benzinga

Topics ETFs

Novo Nordisk Pops 8% On 'Significant' Weight Loss For Oral Wegovy ↗

September 18, 2025

Novo Nordisk stock surged Thursday after its oral version of Wegovy helped patients lose a "significant" amount of weight.

Via Investor's Business Daily

Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study ↗

September 18, 2025

Novo Nordisk's Wegovy cut cardiovascular risks more than tirzepatide in real-world data from patients with obesity and heart disease.

Via Benzinga

Why Is Everyone Talking About Novo Nordisk Stock? ↗

September 18, 2025

Competition in various directions is affecting the company's fastest-growing product.

Via The Motley Fool

3 Dividend Growth Stocks You Can Buy and Forget About ↗

September 18, 2025

These stocks have been raising their payouts for years and they're likely going to continue doing so for the foreseeable future.

Via The Motley Fool

Topics Economy

Krispy Kreme Jumps After Hours Following Kash Patel's Stake Reveal ↗

September 18, 2025

Krispy Kreme's stock rose 3.81% after hours on Wednesday, following FBI Director Kash Patel's testimony about his stock purchase, despite a 68.28% drop in 2025.

Via Benzinga

1 Mega-Cap Stock with Impressive Fundamentals and 2 We Question

September 18, 2025

"Too big to fail" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their...

Via StockStory

Topics Artificial Intelligence

Novo Nordisk Stock Jumps After-Hours On Wegovy Pill Breakthrough As Weight-Loss War With Eli Lilly Heats Up ↗

September 17, 2025

The Danish drugmaker has already filed the once-daily pill with U.S. regulators, aiming for the first FDA-approved oral GLP-1 treatment for obesity.

Via Stocktwits

FBI Director Kash Patel Bought 2 Stocks In 2025 — One's Already A Meme Favorite ↗

September 17, 2025

FBI Director Kash Patel was asked about two stocks he bought earlier this year by a member of Congress on Wednesday and gave a surprising answer. The transactions come as members of Congress are...

Via Benzinga

Why Novo Nordisk Stock Popped Today ↗

September 17, 2025

Novo Nordisk lost half its value over the past year. Is it cheap enough to buy now?

Via The Motley Fool

Congressional Trading Report: Rep. David Taylor Sold Over $2K In Alphabet Stock ↗

September 17, 2025

Via Benzinga

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.